Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03768336 · ClinicalTrials.gov registry record · NA
A Stress Management and Resiliency Program for Adolescent and Young Adult Survivors
A NA study of Cancer, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- NA
- Development phase
- 72
- Enrollment target
- 1
- Study location
NCT03768336: Active NA study of Cancer, sponsored by Massachusetts General Hospital.
NCT03768336 is a NA study of Cancer that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 72 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03768336, a NA study of Cancer, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 72 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study aims to explore the feasibility and acceptability of an adapted resiliency group program, called the Relaxation Response Resiliency Program (3RP-AYA), to reduce stress and promote stress-management among adolescents and young adults who have completed treatment for cancer.
Primary Outcome
Percent of identified eligibles who were approached (hence given the opportunity to participate) who enroll (i.e., sign consent and complete baseline). Qualitative information from experts and participants will be used to inform feasibility.
Conditions Studied
Interventions
- OTHER Waitlist control
- OTHER 3RP-AYA
Study Locations (1)
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2019-04-01 |
| Est. Completion | 2025-08-01 |
| Phase | NA |
What the registry record for NCT03768336 still lists
NCT03768336 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which Waitlist control is the first listed.
NCT03768336 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03768336 about?
NCT03768336 is a clinical study titled "A Stress Management and Resiliency Program for Adolescent and Young Adult Survivors". This research study aims to explore the feasibility and acceptability of an adapted resiliency group program, called the Relaxation Response Resiliency Program (3RP-AYA), to reduce stress and promote stress-management among adolescents and young adults who have completed treatment for cancer.
What is the current status of trial NCT03768336?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 72 participants. The study started on 2019-04-01. Estimated completion is 2025-08-01.
What conditions does trial NCT03768336 study?
This clinical trial studies the following conditions: Cancer.
What interventions are being tested in trial NCT03768336?
The interventions under investigation include: Waitlist control (OTHER), 3RP-AYA (OTHER).
Who is sponsoring clinical trial NCT03768336?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03768336 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03768336's enrollment target sits among peer trials
72 371st of 615 higher than 244 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
BfedBwell Optimization Pilot
RECRUITING · NA
-
Legal Evaluation for Greater Access to Cancer Care (LEGAL-CARE)
RECRUITING · NA
-
Optimizing the AYA Survivors' Coping and Emotional Needs Toolkit
RECRUITING · NA
-
Comprehensive Connected Cancer Care (C4): Intervention Evaluation
RECRUITING · NA
-
Cancer-related Fatigue and Its Biological Contributors in Adolescent and Young Adult Brain Tumor Survivors: Effects of a Tele-exercise Intervention
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI